| Terminated | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers NCT06120504 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Skin Barrier and Microbiome of CTCL Patients NCT05827107 | Centre for Human Drug Research, Netherlands | — |
| Suspended | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL NCT05138458 | Myeloid Therapeutics | Phase 1 / Phase 2 |
| Completed | A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With NCT04998331 | Takeda | — |
| Completed | A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Ce NCT05137847 | Eisai Inc. | — |
| Withdrawn | Study of Photopheresis in the Treatment of Erythrodermic MF and SS NCT03563040 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Terminated | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides NCT03789864 | Indiana University | N/A |
| Withdrawn | Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma NCT03742804 | Yale University | Phase 2 |
| Active Not Recruiting | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma NCT03902184 | Innate Pharma | Phase 2 |
| Terminated | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders NCT03601819 | University of Michigan Rogel Cancer Center | Phase 1 |
| Terminated | PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) NCT03357224 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma NCT03302728 | Peter MacCallum Cancer Centre, Australia | Phase 1 |
| Unknown | CTCL Directed Therapy NCT03116659 | James J. Peters Veterans Affairs Medical Center | EARLY_Phase 1 |
| Completed | AFM13 in Relapsed/Refractory Cutaneous Lymphomas NCT03192202 | Ahmed Sawas | Phase 1 / Phase 2 |
| Terminated | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL NCT02811783 | Elorac, Inc. | Phase 3 |
| Completed | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrom NCT02953301 | 4SC AG | Phase 2 |
| Unknown | AEDV Registry of Primary Cutaneous Lymphoma NCT03646422 | Fundación Academia Española de Dermatología | — |
| Recruiting | Tissue Repository: CTCL Collection Protocol NCT02840747 | Columbia University | — |
| Completed | VircapSeq Virus Detection in Sézary Syndrome NCT02836886 | Columbia University | — |
| Completed | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma NCT02567656 | Rhizen Pharmaceuticals SA | Phase 1 |
| Completed | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory NCT02181218 | Washington University School of Medicine | Phase 1 |
| Terminated | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas NCT02323659 | Polish Lymphoma Research Group | Phase 4 |
| Completed | Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphom NCT01433731 | TetraLogic Pharmaceuticals | Phase 1 |
| Completed | A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Tr NCT01486277 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma NCT00896493 | Stanford University | Phase 2 |
| Completed | CPG 7909 in Patients With Cutaneous T-Cell Lymphoma NCT00043420 | Pfizer | Phase 1 / Phase 2 |
| Completed | Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) NCT00211198 | Eisai Inc. | Phase 4 |
| Completed | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients NCT00051012 | Eisai Inc. | Phase 4 |
| Completed | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients NCT00050999 | Eisai Inc. | Phase 4 |
| Completed | Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 R NCT00001249 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malign NCT00051597 | Seagen Inc. | Phase 1 / Phase 2 |
| No Longer Available | Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-04 NCT00419367 | Merck Sharp & Dohme LLC | — |
| No Longer Available | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 o NCT01196208 | Seagen Inc. | — |